Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare, Inc. today announced progress on Fiscal 2010 Initiatives and financial results for the Quarter ending March 31, 2010.

13 May 2010

LifeWatch Services to launch remote iPad ECG report TeleViewer application

LifeWatch Services, Inc., a subsidiary of LifeWatch AG, will announce the launch of their remote ECG report TeleViewer™ application for the Apple iPad. The iPad application integrates with and enhances the advanced reporting and workflow management capabilities present in their web based applications for all product offerings.

11 May 2010

Treating OSA in truck drivers lowers healthcare costs and disability rates: Study

For commercial motor vehicle drivers with obstructive sleep apnea, effective treatment lowers healthcare costs and disability rates, reports a study in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

23 Apr 2010

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population.

21 Apr 2010

Racial disparities in sleep and health-related quality of life

A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows that having a sleep disturbance is associated with clinically meaningful reductions in health-related quality of life, and the magnitude of this effect varies by race and sleep disorder.

17 Apr 2010

Obstructive sleep apnea more than doubles stroke risk in men

Obstructive sleep apnea (OSA) is associated with an increased risk of stroke in middle-aged and older adults, especially men, according to new results from new research supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Overall, sleep apnea more than doubles the risk of stroke in men.

8 Apr 2010

Obstructive sleep apnea associated with increased risk of stroke in men

Obstructive sleep apnea is associated with an increased risk of stroke in middle-aged and older adults, especially men, according to new results from a landmark study supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

8 Apr 2010

Electronic nose may help identify asthma in patients: CHEST

New evidence shows that an "electronic nose" containing an array of gas sensors may have the ability to identify asthma in patients. Researchers from Italy compared the diagnostic performance of the electronic nose with lung function tests and fraction of exhaled nitric oxide in seven patients with asthma and seven healthy subjects.

6 Apr 2010

VIVUS terminates Luramist development, commercialization agreement with FemPharm

VIVUS, Inc. today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist™, a metered dose transdermal application of testosterone for women.

1 Apr 2010

Vantage Communications becomes agency of record for ImThera Medical

Vantage Communications, an award-winning global PR firm, today announced that it is the agency of record for ImThera Medical, Inc. Within a few months, Vantage Communications successfully promoted ImThera and its medical device technology with original coverage garnered in top-tier publications such as Neurotech Insights, ENToday, The Gray Sheet, Sleep Review, Respiratory & Sleep Management, Respiratory Therapy, Medical Device Daily, and medGadget.

31 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

FDA Advisory Committee to review VIVUS' NDA for Qnexa

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is tentatively scheduled to review the Company's New Drug Application for Qnexa® for the treatment of obesity on July 15, 2010.

26 Mar 2010

Adrenal fatigue: Vitamins, supplements may do more harm than good

Taking vitamins or supplements to treat “adrenal fatigue” may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

23 Mar 2010

Taking dietary supplements for adrenal fatigue may do more harm than good

Taking vitamins or supplements to treat "adrenal fatigue" may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

18 Mar 2010

GE Healthcare introduces OSA diagnostic tool for inpatient cardiac patients

GE Healthcare today introduced MARS® Virtual Sleep Lab (VSL), the first device to provide a streamlined view of quantitative cardiac and sleep apnea analysis from any GE-monitored inpatient bed, helping enhance speed of diagnosis.

16 Mar 2010

Sleep deprivation may increase heart attack risk

On average, people go to work or school on the first Monday of Daylight Savings after sleeping 40 fewer minutes than normal. And recent studies have found there's a higher risk of heart attacks, traffic accidents and workplace injuries on the first Monday of Daylight Savings.

11 Mar 2010

VIVUS granted three additional patents for Qnexa

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

8 Mar 2010

FDA accepts for filing VIVUS' Qnexa NDA

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa®, for the treatment of obesity. The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.

1 Mar 2010

Special issue of NeuroRehabilitation journal devoted to HI-BI published

IOS Press announces publication of a special issue of NeuroRehabilitation: An International Journal devoted specifically to hypoxic-ischemic brain injury (HI-BI), a significant disruption of brain function due to a deficient supply of oxygen to the brain.

24 Feb 2010